Neurocrine Biosciences, Inc. Stock price
Equities
NBIX
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
139.4 USD | +0.24% | +0.60% | +5.83% |
Financials (USD)
Sales 2024 * | 2.21B | Sales 2025 * | 2.52B | Capitalization | 13.88B |
---|---|---|---|---|---|
Net income 2024 * | 492M | Net income 2025 * | 652M | EV / Sales 2024 * | 5.24 x |
Net cash position 2024 * | 2.28B | Net cash position 2025 * | 3.03B | EV / Sales 2025 * | 4.31 x |
P/E ratio 2024 * |
29.7
x | P/E ratio 2025 * |
22.3
x | Employees | 1,400 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.54% |
Latest transcript on Neurocrine Biosciences, Inc.
1 day | +0.24% | ||
1 week | +0.16% | ||
Current month | +6.93% | ||
1 month | +5.39% | ||
3 months | +15.99% | ||
6 months | +24.00% | ||
Current year | +5.83% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Director of Finance/CFO | 44 | 17-10-31 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-11-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 99-03-31 |
George Morrow
BRD | Director/Board Member | 72 | 15-09-30 |
Kevin Gorman
FOU | Founder | 66 | 91-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.65% | 227 M€ | +9.20% | - | |
3.81% | 1 M€ | -.--% | - | |
1.85% | 8 M€ | +5.61% | ||
1.08% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 139.4 | +0.24% | 664,683 |
24-03-15 | 139.1 | -0.04% | 1,739,211 |
24-03-14 | 139.2 | -1.86% | 1,182,246 |
24-03-13 | 141.8 | +2.95% | 1,073,582 |
24-03-12 | 137.7 | -0.63% | 650,983 |
Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.83% | 13.84B | |
+1.10% | 105B | |
+9.29% | 104B | |
-3.00% | 22.09B | |
-11.89% | 21.98B | |
-26.59% | 20.17B | |
-5.20% | 19.49B | |
-6.58% | 17.75B | |
+7.46% | 11.64B | |
+28.56% | 11.55B |